Articles dans des revues avec comité de lecture (396)
  1. 157. Aftimos, P., Wiedig, M., Langouo Fontsa, M., Awada, A., Ghanem, G. E., & Journé, F. (2013). Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. International journal of oncology, 43(3), 919-926. doi:10.3892/ijo.2013.2008
  2. 158. Stuurman, F., Voest, E., Awada, A., Witteveen, P., Bergeland, T., Hals, P. A., Rasch, W., Schellens, J. J., & Hendlisz, A. (2013). Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. Investigational new drugs, 31(4), 959-966. doi:10.1007/s10637-013-9925-z
  3. 159. Ades Moraes, F., de Azambuja, E., Daugaard, G., Ameye, L., Moulin Correa, C., Paesmans, M., De Jong, D., Decoster, L., De Greve, J., Ismael, G., Møller, A. K., Piccart-Gebhart, M., & Awada, A. (2013). Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). Journal of chemotherapy, 25(4), 239-246. doi:10.1179/1973947813Y.0000000085
  4. 160. Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., Goeminne, J. C., Graas, M.-P., Kennedy, M. J., Ciruelos Gil, E. M., Schneeweiss, A., Zubel, A., Groos, J., Melezínková, H., & Awada, A. (2013). Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of clinical oncology, 31(20), 2586-2592. doi:10.1200/JCO.2012.46.2408
  5. 161. Hendlisz, A., Charette, N., Awada, A., & Deleporte, A. (2013). Academic versus industry-driven research in upper gastrointestinal cancer: sinners and saints. Current opinion in oncology, 25(4), 407-408. doi:10.1097/CCO.0b013e3283622c9e
  6. 162. Awada, A., Dumez, H., Hendlisz, A., Wolter, P., Besse-Hammer, T., Uttenreuther-Fischer, M., Stopfer, P., Fleischer, F., Piccart-Gebhart, M., & Schöffski, P. (2013). Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Investigational new drugs, 31(3), 734-741. doi:10.1007/s10637-012-9880-0
  7. 163. Alameddine, R. R., Otrock, Z. Z., Awada, A., & Shamseddine, A. (2013). Crosstalk between HER2 signaling and angiogenesis in breast cancer: Molecular basis, clinical applications and challenges. Current opinion in oncology, 25(3), 313-324. doi:10.1097/CCO.0b013e32835ff362
  8. 164. Awada, A., & Aftimos, P. (2013). Targeted therapies of solid cancers: New options, new challenges. Current opinion in oncology, 25(3), 296-304. doi:10.1097/CCO.0b013e32835ff318
  9. 165. Hendlisz, A., Golfinopoulos, V., Deleporte, A., Paesmans, M., Mansy, H. E., Garcia, C., Peeters, M., Annemans, L., Vandeputte, C., Maetens, M. M., Borbath, I., Dresse, D., Houbiers, G., Fried, M., Awada, A., Piccart-Gebhart, M., Van Laethem, J.-L., & Flamen, P. (2013). Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC cancer, 13, 190. doi:10.1186/1471-2407-13-190
  10. 166. El Hajj, P., Journé, F., Wiedig, M., Laïos, I., Salès, F., Galibert, M.-D., Van Kempen, L. C., Spatz, A., Badran, B., Larsimont, D., Awada, A., & Ghanem, G. E. (2013). Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. British Journal of Cancer, 108(8), 1641-1647. doi:10.1038/bjc.2013.115
  11. 167. Vanderbeeken, M., Aftimos, P., & Awada, A. (2013). Topoisomerase inhibitors in metastatic breast cancer: Overview of current practice and future development. Current Breast Cancer Reports, 5(1), 31-41. doi:10.1007/s12609-012-0098-0
  12. 168. Von Minckwitz, G., Martin, M., Wilson, G. G., Alba, E., Schmidt, M., Biganzoli, L., & Awada, A. (2013). Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Critical reviews in oncology/hematology, 85(3), 315-331. doi:10.1016/j.critrevonc.2012.09.009
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>